GBA to decide on future of Merck's ezetimibe after German assessment sees no benefit
This article was originally published in Scrip
Executive Summary
IQWiG, Germany's Institute for Quality and Efficacy in Healthcare, says that the benefits of the hypolipidaemic combination product ezetimibe are not clear. The institute's report does not bode well for Merck & Co, which markets Zetia (ezetimibe) and Vytorin (ezetimibe plus simvastatin). The company must not await the verdict of the GBA, the Federal Joint Committee, which makes decisions on reimbursement, whether or not to take action on the report. It "undermines the drug and adds weight to the argument that it should not be prescribed so widely," says Gideon Heap, an analyst at Datamonitor.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.